ABBV - ImmunoGen downgraded on Wall Street expecting AbbVie deal success
2023-12-01 08:52:41 ET
More on AbbVie, ImmunoGen, etc.
- AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology
- AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained
- AbbVie: Get Ready For More Painful Downside
- AbbVie-ImmunoGen buyout deal lifts ADC-focused biotechs
- Biggest stock movers today: Snap, ImmunoGen, Snowflake, Salesforce and more
For further details see:
ImmunoGen downgraded on Wall Street expecting AbbVie deal success